A Single Arm Study of Acalabrutinib Conbimed With Obinutuzumab in Chinese Patients With Previously Untreated CLL

NCT05950997 · clinicaltrials.gov ↗

NA

Phase

RECRUITING

Status

89

Enrollment

OTHER

Sponsor class

Conditions

Chronic Lymphocytic Leukemia

Interventions

DRUG: Acalabrutinib
DRUG: Obinutuzumab

Sponsor

The First Affiliated Hospital with Nanjing Medical University

Collaborators

[object Object]